Asset profile
Diranersen
RNA / oligonucleotide
Evidence outlook · lead readout
NCT03186989 · Mild Alzheimer's Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT03186989: This dose-escalation study randomized participants to diranersen or placebo with both participants and staff blinded, but its primary endpoint was safety and tolerability rather than a cognitive or clinical outcome, which limits what it can show about therapeutic effect.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.